EP3497209A4 - Chimäre pockenviruszusammensetzungen und verwendungen davon - Google Patents

Chimäre pockenviruszusammensetzungen und verwendungen davon Download PDF

Info

Publication number: EP3497209A4
Authority: EP; European Patent Office
Prior art keywords: chimean; virus compositions; small virus; compositions; small
Prior art date: 2016-08-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP17840232.7A

Other languages

English (en)

French (fr)

Other versions

EP3497209A1 (de

Inventor

Yuman Fong

Nanhai Chen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

City of Hope

Original Assignee

City of Hope

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-08-09

Filing date

2017-08-09

Publication date

2020-07-29

2017-08-09 Application filed by City of Hope filed Critical City of Hope

2019-06-19 Publication of EP3497209A1 publication Critical patent/EP3497209A1/de

2020-07-29 Publication of EP3497209A4 publication Critical patent/EP3497209A4/de

Status Pending legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP17840232.7A 2016-08-09 2017-08-09 Chimäre pockenviruszusammensetzungen und verwendungen davon Pending EP3497209A4 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662372408P	2016-08-09	2016-08-09
US201762519010P	2017-06-13	2017-06-13
PCT/US2017/046163 WO2018031694A1 (en)	2016-08-09	2017-08-09	Chimeric poxvirus compositions and uses thereof

Publications (2)

Publication Number	Publication Date
EP3497209A1 EP3497209A1 (de)	2019-06-19
EP3497209A4 true EP3497209A4 (de)	2020-07-29

Family

ID=61163330

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17840232.7A Pending EP3497209A4 (de)	2016-08-09	2017-08-09	Chimäre pockenviruszusammensetzungen und verwendungen davon

Country Status (11)

Country	Link
US (2)	US12084687B2 (de)
EP (1)	EP3497209A4 (de)
JP (4)	JP7023929B2 (de)
KR (3)	KR20250067190A (de)
CN (3)	CN118853594A (de)
AU (2)	AU2017311380A1 (de)
BR (1)	BR112019002646A2 (de)
CA (1)	CA3033512A1 (de)
MX (1)	MX2019001672A (de)
RU (2)	RU2757002C2 (de)
WO (1)	WO2018031694A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014100615A1 (en)	2012-12-20	2014-06-26	Purdue Research Foundation	Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
JP2018510143A (ja)	2015-02-25	2018-04-12	メモリアルスローンケタリングキャンサーセンター	不活化非複製改変ワクシニアウイルスアンカラ（ｍｖａ）の固形腫瘍のための単独療法又は免疫チェックポイント遮断剤併用における使用
CN107847534B (zh)	2015-04-17	2022-10-04	纪念斯隆凯特琳癌症中心	Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
BR112018016948A2 (pt)	2016-02-25	2019-01-08	Memorial Sloan Kettering Cancer Center	mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos
EP3419648A4 (de)	2016-02-25	2019-09-11	Memorial Sloan-Kettering Cancer Center	Replikationskompetente abgeschwächte vaccinia-viren mit deletion der thymidinkinase mit und ohne expression von menschlichem flt3l oder gm-csf für die krebsimmuntherapie
US12144850B2 (en)	2016-04-08	2024-11-19	Purdue Research Foundation	Methods and compositions for car T cell therapy
CA3033512A1 (en) *	2016-08-09	2018-02-15	City Of Hope	Chimeric poxvirus compositions and uses thereof
ES3010559T3 (en)	2017-02-28	2025-04-03	Endocyte Inc	Compositions and methods for car t cell therapy
US11242509B2 (en)	2017-05-12	2022-02-08	Memorial Sloan Kettering Cancer Center	Vaccinia virus mutants useful for cancer immunotherapy
CN111163803B (zh) *	2017-08-11	2025-05-09	希望之城公司	表达car t细胞靶物的溶瘤病毒及其用途
JP7549303B2 (ja)	2018-01-22	2024-09-11	エンドサイト・インコーポレイテッド	Ｃａｒｔ細胞の使用方法
CN112105382A (zh)	2018-02-23	2020-12-18	恩多塞特公司	用于car t细胞疗法的顺序方法
JP2021516957A (ja) *	2018-03-07	2021-07-15	トランジェーヌＴｒａｎｓｇｅｎｅ	パラポックスウイルスベクター
WO2019213173A1 (en) *	2018-04-30	2019-11-07	City Of Hope	Neural stem cell compositions including chimeric poxviruses for cancer treatment
US12252702B2 (en)	2018-09-15	2025-03-18	Memorial Sloan Kettering Cancer Center	Recombinant poxviruses for cancer immunotherapy
CN113583977B (zh) *	2020-04-30	2025-06-06	杭州康万达医药科技有限公司	可受微小rna调控的分离的重组溶瘤痘病毒及其应用
GB2614309A (en)	2021-12-24	2023-07-05	Stratosvir Ltd	Improved vaccinia virus vectors
WO2023213763A1 (en) *	2022-05-02	2023-11-09	Transgene	Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
JP2025528219A (ja)	2022-08-18	2025-08-26	トランジェーヌ	キメラポックスウイルス
AU2024280931A1 (en) *	2023-05-26	2025-11-27	Probiogen Ag	Rapid selection system for the generation of recombinant enveloped viruses
WO2025184411A1 (en)	2024-02-27	2025-09-04	Calidi Biotherapeutics (Nevada), Inc.	Serum-resistant eev viruses and uses thereof
CN120718864B (zh) *	2025-08-28	2025-11-28	山东农业大学	一种高度不成熟鸭坦布苏病毒及其培养方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015103438A2 (en) *	2014-01-02	2015-07-09	Genelux Corporation	Oncolytic virus adjunct therapy with agents that increase virus infectivity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT406376B (de) *	1998-01-16	2000-04-25	Immuno Ag	Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
JP2003528605A (ja)	2000-03-28	2003-09-30	ユニヴァーシティーオヴロチェスター	ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法
EA012723B1 (ru) *	2002-11-25	2009-12-30	Бавариан Нордик А/С	Рекомбинантный поксвирус, содержащий по меньшей мере два промотора ati вируса коровьей оспы, и его применение
AU2004289953B2 (en) *	2003-06-18	2008-09-25	Genelux Corporation	Modified recombinant vaccina viruses and other microorganisms, uses thereof
US20090098529A1 (en)	2006-10-16	2009-04-16	Nanhai Chen	Methods for attenuating virus strains for diagnostic and therapeutic uses
DK2212423T3 (en) *	2007-11-19	2015-03-16	Transgene Sa	oncolytic poxvirus vectors
CA2795695A1 (en) *	2010-04-09	2011-10-13	The University Of Tokyo	Microrna-controlled recombinant vaccinia virus and use thereof
ES2733211T3 (es)	2011-04-15	2019-11-28	Genelux Corp	Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
CN104768567B (zh)	2012-05-18	2017-07-11	奥塔哥创业有限公司	用于伤口愈合的联合治疗和组合物
CA3033512A1 (en) *	2016-08-09	2018-02-15	City Of Hope	Chimeric poxvirus compositions and uses thereof

2017
- 2017-08-09 CA CA3033512A patent/CA3033512A1/en active Pending
- 2017-08-09 CN CN202410528631.4A patent/CN118853594A/zh active Pending
- 2017-08-09 RU RU2019106319A patent/RU2757002C2/ru active
- 2017-08-09 KR KR1020257014373A patent/KR20250067190A/ko active Pending
- 2017-08-09 EP EP17840232.7A patent/EP3497209A4/de active Pending
- 2017-08-09 CN CN201780062335.8A patent/CN110199018B/zh active Active
- 2017-08-09 RU RU2021128158A patent/RU2021128158A/ru unknown
- 2017-08-09 CN CN202410528486.XA patent/CN118834840A/zh active Pending
- 2017-08-09 US US16/324,541 patent/US12084687B2/en active Active
- 2017-08-09 KR KR1020237024342A patent/KR20230113832A/ko not_active Ceased
- 2017-08-09 KR KR1020197006987A patent/KR102557818B1/ko active Active
- 2017-08-09 MX MX2019001672A patent/MX2019001672A/es unknown
- 2017-08-09 WO PCT/US2017/046163 patent/WO2018031694A1/en not_active Ceased
- 2017-08-09 BR BR112019002646-0A patent/BR112019002646A2/pt active IP Right Grant
- 2017-08-09 AU AU2017311380A patent/AU2017311380A1/en not_active Abandoned
- 2017-08-09 JP JP2019507161A patent/JP7023929B2/ja active Active
2022
- 2022-02-08 JP JP2022017693A patent/JP7395628B2/ja active Active
2023
- 2023-11-20 AU AU2023270200A patent/AU2023270200A1/en active Pending
- 2023-11-28 JP JP2023200433A patent/JP7631485B2/ja active Active
2024
- 2024-07-17 US US18/776,109 patent/US20250084384A1/en active Pending
2025
- 2025-02-04 JP JP2025016649A patent/JP2025072482A/ja active Pending

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015103438A2 (en) *	2014-01-02	2015-07-09	Genelux Corporation	Oncolytic virus adjunct therapy with agents that increase virus infectivity

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ANTOINE G ET AL: "The Complete Genomic Sequence of the Modified Vaccinia Ankara Strain: Comparison with Other Orthopoxviruses", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 244, no. 2, 10 May 1998 (1998-05-10), pages 365 - 396, XP004445824, ISSN: 0042-6822, DOI: 10.1006/VIRO.1998.9123 *
BLASCO R ET AL: "Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 67, no. 6, 1 June 1993 (1993-06-01), pages 3319 - 3325, XP002409050, ISSN: 0022-538X *
CHAURASIYA SHYAMBABU ET AL: "A chimeric poxvirus with(thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models", CANCER GENE THERAPY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 27, no. 3-4, 17 June 2019 (2019-06-17), pages 125 - 135, XP037096068, ISSN: 0929-1903, [retrieved on 20190617], DOI: 10.1038/S41417-019-0114-X *
CHAURASIYA SHYAMBABU ET AL: "A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer", MOLECULAR THERAPY- METHODS & CLINICAL DEVELOPMENT, vol. 24, 1 March 2022 (2022-03-01), GB, pages 102 - 116, XP093080747, ISSN: 2329-0501, DOI: 10.1016/j.omtm.2021.12.002 *
KIRN DAVID H. ET AL: "Enhancing Poxvirus Oncolytic Effects through Increased Spread and Immune Evasion", CANCER RESEARCH, vol. 68, no. 7, 1 April 2008 (2008-04-01), pages 2071 - 2075, XP093080710, ISSN: 0008-5472, Retrieved from the Internet <URL:https://aacrjournals.org/cancerres/article-pdf/68/7/2071/2593611/2071.pdf> DOI: 10.1158/0008-5472.CAN-07-6515 *
L. QIN ET AL: "Genome Scale Patterns of Recombination between Coinfecting Vaccinia Viruses", JOURNAL OF VIROLOGY., vol. 88, no. 10, 26 February 2014 (2014-02-26), US, pages 5277 - 5286, XP055310410, ISSN: 0022-538X, DOI: 10.1128/JVI.00022-14 *
MERCER A A ET AL: "A Novel Strategy for Determining Protective Antigens of the Parapoxvirus, Orf Virus", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 229, no. 1, 3 March 1997 (1997-03-03), pages 193 - 200, XP004460173, ISSN: 0042-6822, DOI: 10.1006/VIRO.1996.8433 *
MICHAEL P. O'LEARY ET AL: "A Novel Oncolytic Chimeric Orthopoxvirus Encoding Luciferase Enables Real-Time View of Colorectal Cancer Cell Infection", MOLECULAR THERAPY - ONCOLYTICS, vol. 9, 1 June 2018 (2018-06-01), pages 13 - 21, XP055659837, ISSN: 2372-7705, DOI: 10.1016/j.omto.2018.03.001 *
See also references of WO2018031694A1 *
WOODROOFE G M ET AL: "Genetic studies with mammalian poxviruses - IV. Hybridization between several different poxviruses", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 12, no. 2, 1 October 1960 (1960-10-01), pages 272 - 282, XP023055341, ISSN: 0042-6822, [retrieved on 19601001], DOI: 10.1016/0042-6822(60)90200-2 *

Also Published As

Publication number	Publication date
JP2019524131A (ja)	2019-09-05
KR102557818B1 (ko)	2023-07-20
KR20190038626A (ko)	2019-04-08
CN118853594A (zh)	2024-10-29
KR20230113832A (ko)	2023-08-01
AU2017311380A1 (en)	2019-03-28
RU2019106319A3 (de)	2021-03-17
RU2019106319A (ru)	2020-09-17
BR112019002646A2 (pt)	2019-10-08
WO2018031694A1 (en)	2018-02-15
RU2021128158A (ru)	2022-04-07
JP2025072482A (ja)	2025-05-09
MX2019001672A (es)	2019-06-06
JP7631485B2 (ja)	2025-02-18
JP2024026191A (ja)	2024-02-28
AU2023270200A1 (en)	2024-01-25
KR20250067190A (ko)	2025-05-14
RU2757002C2 (ru)	2021-10-08
CN110199018A (zh)	2019-09-03
JP7395628B2 (ja)	2023-12-11
JP2022065034A (ja)	2022-04-26
US20190218522A1 (en)	2019-07-18
US12084687B2 (en)	2024-09-10
US20250084384A1 (en)	2025-03-13
EP3497209A1 (de)	2019-06-19
CN118834840A (zh)	2024-10-25
CA3033512A1 (en)	2018-02-15
CN110199018B (zh)	2024-06-07
JP7023929B2 (ja)	2022-02-22

Publication	Publication Date	Title
EP3497209A4 (de)	2020-07-29	Chimäre pockenviruszusammensetzungen und verwendungen davon
EP3607044C0 (de)	2024-11-13	Reinigungsmittelzusammensetzungen und verwendungen davon
EP3474820C0 (de)	2024-02-07	Glp-1-zusammensetzungen und verwendungen davon
EP3411412A4 (de)	2020-03-18	Fabs-in-tandem-immunglobulin und verwendungen davon
PL3443009T3 (pl)	2022-01-31	Przeciwciała i kompozycje anty-tim-3
DK3805376T3 (da)	2025-09-29	Modificeret virus
EP3485007C0 (de)	2025-10-29	Neuartige esterasen und verwendungen davon
EP3485006C0 (de)	2025-10-29	Neuartige esterasen und verwendungen davon
DK3565568T3 (da)	2025-09-01	Ændret virus
PL3407888T3 (pl)	2021-08-30	Związki pirydopirolochinoksaliny, ich kompozycje i zastosowania
EP3478308A4 (de)	2020-07-22	Cannabiszusammensetzungen und -verfahren
EP3464374C0 (de)	2025-08-06	Baff-r-antikörper und verwendungen davon
EP3397709C0 (de)	2023-10-11	Oligoester und zusammensetzungen daraus
EP3481952A4 (de)	2020-04-15	Leukämiemethylierungsmarker und verwendungen davon
DK3102555T3 (da)	2021-08-09	Sammensætninger af forbindelser og anvendelser deraf
EP3522882A4 (de)	2020-06-24	Aminosäurezusammensetzungen und verwendungen davon
PL3500255T3 (pl)	2023-03-13	Farmaceutyczne kompozycje okulistyczne i powiązane z nimi zastosowania
DK3494119T3 (da)	2024-12-02	Forbindelser og sammensætninger og anvendelser deraf
EP3583219A4 (de)	2021-04-14	Probiotische zusammensetzungen und verwendungen dafür
EP3478264C0 (de)	2025-11-19	Nikotinpartikel und zusammensetzungen
EP3893945A4 (de)	2022-11-30	Cromolynester und verwendungen davon
PT3261437T (pt)	2019-11-29	Compostos e composições fungicidas
EP3498777A4 (de)	2020-01-22	Organopolysiloxanemulsionszusammensetzung und harzzusammensetzung
EP3258948C0 (de)	2023-12-06	Anti-entzündliche und immunomodulatorische zusammensetzungen, enthaltend klebsormidium und verwendungen davon
EP3310373A4 (de)	2019-02-13	Thiol-en-basierte peptidheftung und verwendungen davon

Legal Events

Date	Code	Title	Description
2018-02-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-05-17	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-05-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-06-19	17P	Request for examination filed	Effective date: 20190228
2019-06-19	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-06-19	AX	Request for extension of the european patent	Extension state: BA ME
2019-11-13	DAV	Request for validation of the european patent (deleted)
2019-11-13	DAX	Request for extension of the european patent (deleted)
2020-03-04	RIC1	Information provided on ipc code assigned before grant	Ipc: C12N 15/863 20060101ALI20200124BHEP Ipc: A61K 35/76 20150101ALI20200124BHEP Ipc: A61K 31/7088 20060101ALI20200124BHEP Ipc: C07K 16/28 20060101ALI20200124BHEP Ipc: C12N 7/01 20060101AFI20200124BHEP Ipc: C07K 14/47 20060101ALI20200124BHEP
2020-07-29	A4	Supplementary search report drawn up and despatched	Effective date: 20200626
2020-07-29	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 14/47 20060101ALI20200622BHEP Ipc: C07K 16/28 20060101ALI20200622BHEP Ipc: C12N 15/863 20060101ALI20200622BHEP Ipc: C12N 7/01 20060101AFI20200622BHEP Ipc: A61K 31/7088 20060101ALI20200622BHEP Ipc: A61K 35/76 20150101ALI20200622BHEP
2022-12-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2023-01-25	17Q	First examination report despatched	Effective date: 20221222
2023-08-25	TPAC	Observations filed by third parties	Free format text: ORIGINAL CODE: EPIDOSNTIPA